ADCT-402-103 (R/R)

A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Study treatments

Loncastuximab tesirine (ADCT-402) + ibrutinib

Inclusion criteria

• 18 years or older
• Mantle cell lymphoma
• Patients with DLBCL must have relapsed or refractory disease and have failed or been intolerant to available standard therapy
• Patients who have received previous CD19-directed therapy must have a biopsy which shows CD19 expression after completion of the CD19-directed therapy
• Measurable disease
• ECOG score 0-2

Exclusion criteria

• Known history of hypersensitivity to or positive serum human ADA to a CD19 antibody
• Allogenic or autologous transplant within 60 days prior to start of study drugs (C1D1)
• Active graft-versus-host disease

Participating sites

• CHU UCL Namur - site Mont-Godinne